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1. Introduction 
The premalignant lesions of vulvar intraepithelial neoplasia (VIN) involve the mucosal 
and/or cutaneous epithelium of the vulva. VIN may be HPV-related VIN (usual VIN) or – 
unrelated and represents the most frequent vulvar cancer precursors. Usual VIN occurs in 
adult women and commonly resembles persistent anogenital warts which are often 
multifocal pigmented papular lesions. It is caused by high-risk HPV (HR-HPV) types, 
essentially 16 in up to 91% of the cases (Srodon et al, 2006), and histologically, it is made 
of poorly to undifferentiated basal cells and/or highly atypical squamous epithelial cells 
(McClugagge et al, 2009). The involvement of the entire thickness of the epithelium 
defines the grade 3 of the disease (VIN3). The disease progresses towards invasion in 
about 3% of treated patients and 9% of the untreated ones according to a review of over 
3,000 cases (van Seters et al, 2005) whereas evolution towards invasive carcinoma is 
observed in about 30% of untreated grade 3 cervical intraepithelial neoplasia (CIN3) 
patients (Ostor et al, 1993).  
2. Virology 
HPVs are DNA viruses with a circular double strain genome including 8 000 base pairs. The 
genome is divided into three regions: a Long Control Region which controls viral 
replication, a region coding for Early proteins (E1 to E7, including the E6 and E7 proteins 
that share oncogenic and transforming properties), and a region coding for Late proteins 
such as L1 and L2 proteins that constitute 80% and 20% of the viral capside, respectively. 
More than 150 HPV have been sequenced, one HPV being considered different from another 
when there is a difference in 10% of nucleotides coding for L1 genes. 
Following a breach in the malpighian pluristratified epithelium, HPVs infect basal stem cells 
of keratinocytes. The virus initially remains in episomal form with synthesis of E2 protein. 
This protein is a major regulator of viral vegetative cycle and is required for transcriptional 
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regulation as well as viral DNA replication together with the E1 helicase (Desaintes et al, 
1996). In contrast, E2 is generally undetectable in cancers due to a preferential integration of 
the viral genome in the cell genome and disruption of the E2 open reading frame (Berumen 
et al, 1994; Collins et al, 2009). Therefore E2 is a marker of viral infection and is specific for 
the early stages of the viral gene expression in infected cells. This was formally 
demonstrated in a recent work that showed a strong staining of the E2 protein in the 
intermediate differentiated layers of HPV16-infected tissues and low grade CIN (Xue et al, 
2010). The high expression of HPV16 E2 in low grade lesions therefore represents a marker 
for HPV infection even before any clinical manifestation.  
After integration of the genome of oncogenic HPVs such as HPV16 into the host genome, 
viral oncogenic E6 and E7 proteins are synthesized in large quantities in the inner third of 
the epithelium. E6 links to p53 and induces its degradation by the ubiquitin pathway and E7 
links to pRB and allows the release of growth factors such as E2F.  
During maturation of keratinocytes from the basal layer to the epithelial surface, viral 
capside proteins L1 and L2 are synthesized and expressed at the surface of mature 
keratinocytes in order to form a new viral particle which is able to infect adjacent healthy 
epithelium and to contaminate sexual partners.  
3. Epidemiology of HPV16 related VIN 
HPV infections occur preferentially in young women under 25 years of age (Boulanger et al, 
2004). Several stages of lesions can be observed following oncogenic HPV infection. The first 
stage is a simple infection of keratinocytes that become koilocytes. The following stages are 
related to the transformation of infected keratinocytes into malignant cells. The depth at 
which malignant cells are found defines the disease stage. High grade squamous 
intraepithelial lesions as VIN3 are diagnosed on the basis of biopsy, with malignant cells in 
entire thickness of the epithelium 
The premalignant lesions of HPV-related grade 3 intraepithelial neoplasia involve the 
mucosal and/or cutaneous epithelium of the vulva (usual VIN or VIN3), perineal and 
perianal region. Usual VIN occurs in adult women and commonly resembles persistent 
anogenital warts that are more often multifocal pigmented papular lesions disseminated on 
the vulva and/or the perianal skin than monofocal unique lesion (Figure 1). 
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Fig. 1. Clinical presentations of usual multifocal or monofocal vulvar and preineal 
intraepithelial neoplasia 
4. Why does usual VIN can spontaneously regress?  
Although usual VIN lesions are often chronic and recurrent, they can regress spontaneously 
in up to 35% of young (less than 30 years) women presenting with multiple pigmented 
lesions within a median duration of 9.5 months (Jones et al, 2005} (Bourgault Villada, 2010). 
We previously studied a patient who presented with multifocal usual VIN and showed a 
complete clearance of viral lesions eight months after disease onset and two months after 
electrocoagulation of less than 50% of the usual VIN lesions (Bourgault Villada et al, 2004). 
Immunohistochemical study of her initial vulvar biopsy revealed a marked dermal infiltrate 
containing a majority of CD4+ T lymphocytes and an epidermal infiltrate made up of both 
CD4+ and CD8+ T cells (Figure 2). She showed also a proliferating response against one 
peptide from E6 protein and a high frequency anti-E6 and anti-E7 effector blood T cells by ex 
vivo IFN ELISpot assay just before clinical regression (Figure 3). Such a study of blood 
cellular immune responses together with the analysis of vulvar biopsies obtained 
simultaneously and correlated to clinical outcome was not previously reported. In an anti-
HPV vaccine trial conducted by Davidson and al (Davidson et al, 2003), usual VIN lesions 
completely regressed in a patient following vaccination. Interestingly, immunostaining of 
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vulvar biopsy prior to the vaccine showed a marked CD4+ and CD8+ T lymphocyte 
infiltrate of both epithelial and sub-epithelial sheets. One may wonder whether the 
regression of these patient lesions could be related to a spontaneous regression. Therefore, 
the observation of a CD4+ and CD8+ infiltrate within sub-epithelial and epithelial sheets in 
the biopsy and the visualization of very strong blood anti-HPV T cell responses in patient 
with usual VIN could be predictive of spontaneous clinical outcome. It may also be thought 
that high numbers of blood CD4+ and CD8+ lymphocytes after therapeutic vaccination could 
allow clearance of HPV-16 lesions in usual VIN, assuming that anti-HPV vaccine-induced T 
effector cells could home in the HPV cutaneous and mucosal lesions. 
 
CD3 lymphocytes CD8 lymphocytes CD4 lymphocytes 
 
Fig. 2. Immunohistochemical study of the vulvar biopsy just before spontaneous regression 
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Fig. 3. IFNELISpot assay performed just before clinical regression 
5. What is the exact role of cellular HPV16-specific T-cell responses?  
Cellular immunity (CD4+ and CD8+ T-cells) plays a key role in the defense against all HPV-
induced infections or lesions by destroying HPV-infected or -transformed keratinocytes. 
Indeed, the incidence of HPV infections and diseases significantly increases with CD4+ T cell 
impairment in immunosuppressed such as transplanted (Arends et al, 1997) or HIV-infected 
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patients (Sun et al, 1997). In asymptomatic HPV16 infections, most women resolve 
spontaneously their infection without clinical disease concomitantly with blood anti-HPV16 
Th1 CD4+ T cell responses (Welters et al, 2003). Similarly, regression of condyloma is 
associated with a dense epithelial cellular infiltrate made up of both CD4+ and CD8+ T 
lymphocytes with a Th1 cytokine profile as measured by cytokine mRNAs in interferon 
(IFN)-treated condylomas (Coleman et al, 1994). Proliferative CD4+ T cell responses are also 
associated with spontaneously regressive CIN3 (Kadish et al, 1997). The evolution of CIN3 
towards invasive cancers is featured by a decrease of CD4+ cellular infiltrate, an increase of 
CD8+ T lymphocytes (Ghosh et al, 1992) with impairment of HPV16-specific CTL responses 
which could be related to a down- regulation of MHC class I molecules on HPV-16-infected 
cells and to the appearance of suppressive T lymphocytes (Treg) and a loss of blood anti-
HPV-16 CD4+ activity. In high grade cervical intraepithelial neoplasia (CIN), positive intra-
dermal reaction after intra-dermal injection of 5 HPV-16 E7 large peptides correlated with 
the spontaneous clearance of the lesions, which further indicates the presence and the very 
important role of HPV specific CD4+ T lymphocytes (Hopfl et al, 2000).  
6. Anti-E2 T-cell responses are a marker of clinical viral control  
We recently tested in a longitudinal study of 18 months, by proliferative assays, intracellular 
cytokines synthesis and IFNELISpot, the cellular immune responses against the HPV16 E2 
protein that is early synthesized after HPV infection when the virus is episomal in eight 
women presenting with HPV16-related usual VIN and their healthy male partners (Jacobelli 
et al, 2011, unpublished data). In six women, we showed that anti-E2 polyfunctional CD4 T-
cell responses (proliferative responses and synthesis of IFN and/or IL2) appear when the 
clinical lesions heal after treatment or when the HPV infection remains silent. In the women 
presenting with persistent lesions, no proliferation was observed. 
Blood proliferative T-cell responses against HPV16 E2 peptides have been also observed in 
50% of healthy women, who presumably previously cleared HPV16 infection (de Jong et al, 
2004) and in 9 out of 22 regressive CIN3 cases (Dillon et al, 2007). In another studies, the lack 
of anti-E2 proliferative responses was reported in 16 of 18 patients (89%) affected with usual 
VIN lesions (Davidson et al, 2003) and in 7 of 8 and 9 of 12 women affected with CIN3 
(Dillon et al, 2007; de Jong et al, 2004).These observations reinforce the strong role of T-cells 
in the control of HPV replication. 
7. Why the male partners do not have any HPV16-related lesions?  
Men are vectors of oncogenic HPV infection (Buckley et al, 1981; Giuliano et al, 2011). 
However, while HPV infection was found in 71 to 90% of the partners of HPV-infected 
women (Hippelainen et al, 1994; Nicolau et al, 2005), only 52% harbored the same HPV 
subtypes (Reiter et al, 2010). Moreover, penile intra-epithelial neoplasia is rare and detected 
in less than 2% of the men in contact with oncogenic HPV (Giraldo et al, 2008). We thus 
analyzed HPV infection and anti-HPV16 E2 blood T-cell responses in asymptomatic male 
partners chronically exposed to HPV16 during sexual intercourses with their wives affected 
with usual VIN (Jacobelli et al, 2011, unpublished data). We had hypothesized that male 
partners exposed to replicative HPV16 could develop immunologic responses against the 
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early E2 viral protein and thus clear infection. In the absence of condom usage for at least 6 
months, the male partners of women presenting with usual VIN could be contaminated by 
HPV16. HPV16 and HPV27 (a cutaneous HPV) were identified in genital sampling gathered 
by cytobrush in only two of the eight healthy partners. Such a prevalence of contamination 
by HPV16 is similar to the one usually observed in male partner of oncogenic HPV-infected 
women (Reiter et al, 2010). In this male population, we have chosen to study anti-HPV16 E2 
T-cell responses because E2 protein is an early highly expressed protein. E2 is bigger than E6 
and E7 proteins and induces more T-cell responses than E6 and E7. Therefore looking for an 
E2-specific response is then more sensitive. In addition, E2 is required for replication and the 
detection of E2-specific T cell responses is the signature of viral replication. The study of 
anti-E2 T-cell responses is then more appropriate for the early phases of HPV16 infection as 
supposed in male partners of women having usual VIN. We have observed HPV16-E2-
specific proliferative responses in seven and intracellular cytokine synthesis of single IFN, 
dual IFN/IL2 and single IL2 in six out of the seven partners. Since there is no E2 protein in 
the viral particle, the high frequency of E2-specific T cells responses in partners of women 
with usual VIN demonstrates that the virus replicate in males.  
These E2 specific T-cell responses indicate a striking correlation in all male partners but two 
between the absence of the HPV-related lesion. The presence of spontaneous E2-specific 
proliferative T-cell responses and single IFN, dual IFN/IL2, single IL2 T-cell producers was 
previously described in other viral systems (Harari et al, 2006; Pantaleo et al, 2006). These 
polyfunctional anti-E2 T-cell responses could be due to an efficient presentation of viral 
antigens by dendritic cells present in mucosal tissue and it is tempting to speculate that E2-
specific responses are responsible for the clearing of the lesion. Therefore, spontaneously HPV 
control is related to the presence of memory polyfunctional CD4+ T-cells in male partners.  
8. Why the prophylactic vaccine could be useful in men?  
The analysis of E2 specific T cell responses is a sensitive and reliable tool to analyze disease 
progression and the natural history of HPV infection. In six out of eight male partners, the 
presence of T-cell proliferative responses and single IL2, dual IFN/IL2, single IFN memory 
T-cells against HPV16 E2 peptides was concomitant to the control of genital HPV lesions 
despite HPV16 exposure. These results are reminiscent of those described in Gambian 
prostitutes exposed to HIV with presence of anti-HIV cytotoxic T lymphocytes without any 
detectable HIV (Rowland-Jones et al, 1995). Such anti-viral immune T cells responses thus 
reflect an undetectable viral infection. Our experimental results demonstrate for the first time 
that, although not clinically detectable, HPV16 can replicate in men and can induce a strong 
memory T cell response against one of an early viral protein. The presence of polyfunctional 
(IL2, IFN/IL2 and IFN secretions and proliferation) anti E2 CD4+ T-cell responses in 
asymptomatic men unambiguously establishes that E2 is a marker of HPV infection even 
when undetectable lesions. Responses represent correlates of protective antiviral immunity in 
HPV infection. Monofunctional (production of IFN by IFN-ELISpot) “anti-E2 T-cell” 
responses does not allow HPV16 control. These results suggest that male are an important 
reservoir of HPV and provide a strong argument in favor of prophylactic HPV vaccination of 
young men with VLPs to decrease HPV16 infection in men, viral transmission from men to 
women and thus fight against the spread of mucosal HPV diseases in the population.  
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9. How to cure usual VIN? Therapeutic vaccines 
Preventive vaccines do not address the current need for better treatment for women 
previously infected by HPV 16 or 18. Other types of vaccines must be used to increase or 
induce new specific anti-HPV cellular immunity (CD4+ and CD8+ T lymphocytes) in order 
to kill transformed epithelial cells. Several approaches can be used in this aim. To stimulate 
cytotoxic or antiviral CD8+ T lymphocytes, the vaccines must target the cytoplasm of 
dendritic cells. The degradation of vaccine antigens by proteasomes results in short peptides 
that can bind to HLA class I molecules and migrate at the surface of dendritic cells. To 
stimulate CD4+ T lymphocytes, endocytosis of vaccinal antigens is essential, followed by 
degradation of antigens by lysosome/endosome in large peptides that associate with HLA 
class II molecules before migrating at the surface of dendritic cells. All these therapeutic 
vaccines must target E6 and E7 viral proteins and contain recombinant viruses (vaccinia 
viruses for example), DNA or peptides.  
Recently, an open clinical trial was performed by the Melief’s group (Kenter et al, 2009) in 
twenty women presenting with usual VIN using 13 large peptides spanning the whole E6 
and E7 proteins. Forty five percent of complete (9/20 women) and 25 % (5/20) of partial 
remission were observed 12 months after immunization. These important results would be 
even more interesting if the investigators had included a placebo group (Bourgault Villada, 
2010a). A new trial with a placebo group is currently under way.  
Vaccinia virus was also used in a recombinant vaccine containing E6 and E7 genes from 
HPV16 and HPV18 (TA-HPV) to vaccinate usual VIN patients. A clinical complete or partial 
response was observed in 8/18 treated women (Davidson et al, 2003). More recently, 
vaccination against usual VIN was also performed with another recombinant vaccinia virus, 
TA-L2E6E7 from HPV16 (Daayana et al, 2010). Two months before vaccination, 19 women 
were treated by topical imiquimod and then vaccinated by intramuscular route with 3 doses 
of recombinant vaccinia virus. Imiquimod is an immunomodulator that increases the 
synthesis of type I IFN by dendritic cells after its fixation to the TLR7 in human dendritic 
cells. Complete remission was obtained in 58% of vaccinated women.  
10. How to determine the epitopic regions for a therapeutic vaccine?  
In a study including 16 women presenting with usual VIN, we have determined the 
strongly immunogenic regions from HPV16 E6 and E7 proteins for CD4+ and/or CD8+ T 
lymphocytes (Bourgault Villada et al, 2010b). Among 18 large peptides of the proteins E6 
and E7, two were recognized in proliferative assays as immunodominant by T cells from 10 
out of 16 women (62%) at the entry in the  study, namely E6/2 (aa 14-34) and E6/4 (aa 45-68) 
peptides. Four other peptides, E6/7 (aa 91-110), E7/2 (aa 7-27), E7/3 (aa 21-40) and E7/7 (aa 
65-87) were recognized by only 12% of the women in proliferative or IFNELISpot tests. 
The regions of E6 and E7 proteins implicated in T cell recognition during HPV infection 
were not yet well defined because of the usually low frequency of anti-HPV blood T cell 
responses and of the difficulties of their study.  
In protein E6, some peptides included in, including or overlapping our peptides E6/2 (aa 
14-34) and E6/4 (aa 45-68) have already been described as preferentially recognized by 
CD4+ T cells. Among them, peptide E6 42-57 that is restricted by HLA-DR7 has already 
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been identified (Strang et al, 1990). Regions E6 1-31, 22-51 and 24-45 can be also 
immunogenic for CD4+ T cells as shown in CIN or sexually active healthy women (Kadish et 
al, 1997). The region E6 42-71, which includes peptide E6/4 (aa 45-68), has also been 
described as a target of proliferative responses in CIN patients (Kadish et al, 1997). Another 
E6 111-158 region was previously described as inducing proliferative responses in infected 
asymptomatic subjects or in patients with CIN3 (Kadish et al, 1997; Strang et al, 1990) as 
well as E6 127-141 peptide in healthy young women (Gallagher et al, 2007). Similarly, 
peptides E7 43-77, E7 50-62 and E7 58-68 which are restricted by DR3, DR15 and DR17, 
respectively, were defined as epitopic peptides for CD4 + T cells (Strang et al, 1990; van der 
Burg et al, 2001; Wang et al, 2009). E7 region 51-98, including our E7/7 (aa 65-87) peptide, is 
also very immunogenic for proliferating T lymphocytes (de Gruijl et al, 1998; Luxton et al, 
1996; Nakagawa et al, 1996).  
The characterization of E6 and E7 HPV-16 epitopes and the HLA restriction of their 
recognition by CD8+ T lymphocytes are more precise: E6 29-38, E7 11-20, E7 82-90 and E7 
86-93 epitopes are presented by HLA-A2 (Evans et al, 2001; Ressing et al, 1995, 1996), E6 80-
88 and E7 44-52 by HLA-B18 (Bourgault Villada et al, 2000) and E6 49-57 by HLA-A24 
(Morishima et al, 2007). In women who cleared HPV 16 infection, cytotoxic T lymphocytes 
(CTL) responses are directed against epitopes preferentially located in the N-terminal half of 
the E6 protein (region 16-40) (Nakagawa et al, 2005). In this fragment, the dominant epitope 
E6 29-37 is restricted by HLA-B48, E6 31-38 by HLA-B4002 and the subdominant epitope E6 
52-61 by HLA-B35 (Nakagawa et al, 2007). The same group had also shown that the peptide 
E6 33-42 61 is recognized by CD8+ T lymphocytes in association with HLA-A68, peptide E6 
52-61 in association with HLA-B57 and –B35, peptide E6 75-83 in association with HLA-B62, 
peptide E7 7-15 in association with HLA-B48 and peptide E7 79-87 in association with HLA-
B60 (Nakagawa et al, 2004, 2007; Wang et al, 2008). In addition, E7 7-15 is also able to bind 
HLA-A2 and -B8 to be recognized by CTL (Oerke et al, 2005; Ressing et al, 1995). From the 
latter results, two hot spots of CD8+ T-cell epitopes in protein E6 may be located in the 
regions E6 29-38 and 52-61 and another one in protein E7 (E7 7-15) (Nakagawa et al, 2007). 
Nevertheless, a poor immunogenicity of E7 protein was observed in many studies during 
both HPV 16 infection and after peptidic vaccination using long peptides spanning both E6 
and E7 (Kenter et al, 2008; Welters et al, 2008) such as those used in our study. 
The epitopes E6/2 (aa 14-34) and E6/4(aa 45-68) hence could be strongly recognized by 
CD4+ and / or CD8+ T lymphocytes and could be particularly relevant in the design of a 
peptide vaccination. We may hypothesize that the T cell responses that we observed were 
able to contain the tumor cells into the epithelium. Therefore, E6/2 (aa 14-34) and E6/4 (aa 
45-68) peptides could play a major role in the protection against invasive cancer by 
stimulating T lymphocytes. Specific CD4+ T-cells play an essential role in the defense 
against HPV in particular in women presenting with usual VIN and their male partners. 
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